Stock listing

Frankfurt:UR8 UroGen Pharma Ltd. Aktie

German listing (Frankfurt) of UroGen Pharma Ltd. · home listing NASDAQ:URGN

Follow UroGen Pharma Ltd. into a list and get an email when it puts out news.

Share price · FWB:UR8

€27.86 EUR -1.01 (-3.5%)

Close on Nov 20, 2026

Past year +2.4% · daily closes, Nov 20, 2025 – Nov 6, 2026, adjusted for splits
Day range
€27.86 – €28.17 EURNov 20, 2026
Market cap
€1.36B EURAt the close on Nov 20, 2026 · price × 48.88M shares outstanding
52-week range
€14.52 – €42.97 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
€4,272 EURMedian day 0 shares · 41 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026
UroGen Pharma Ltd. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:URGN · Home$27.65 USD-2.14 (-7.2%)2,399,078$31.15$31.90$27.58$29.79Close on Nov 20, 2026
LSE:0XOD$31.83 USD-0.086 (-0.3%)666$31.20$31.83$30.57$31.92Close on Nov 20, 2026
Frankfurt:UR8€27.86 EUR-1.01 (-3.5%)—€28.17€28.17€27.86€28.87Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:UR8 · EUR, adjusted for splits

DayCloseChange%OpenHighLowVolume
€22.00-1.086-4.7%€21.52€23.28€21.44120
€23.08-6.763-22.7%€24.78€24.79€23.082,800
€29.85-0.671-2.2%€29.85€29.85€29.85938
€30.52+0.156+0.5%€30.10€30.57€29.630
€30.36+1.06+3.6%€29.28€30.47€29.130
€29.30-0.614-2.1%€29.30€29.30€29.30266
€29.92-0.946-3.1%€30.04€30.15€29.91484
€30.86+0.321+1.1%€29.93€31.18€29.58100
€30.54+0.513+1.7%€30.24€30.66€30.040
€30.03-0.729-2.4%€30.15€30.28€30.030
€30.76+0.02+0.1%€30.76€30.76€30.760
€30.74-0.756-2.4%€30.74€30.74€30.740
€31.49+0.098+0.3%€30.37€31.58€30.270
€31.39+1.613+5.4%€29.73€31.42€29.720
€29.78-2.035-6.4%€29.73€29.82€29.720
€31.82-0.437-1.4%€31.82€31.82€31.820
€32.25-1.176-3.5%€32.14€32.65€32.070
€33.43-0.0070.0%€33.43€33.43€33.430
€33.44+1.492+4.7%€33.45€33.48€33.390
€31.94-0.382-1.2%€31.94€31.94€31.940
€32.33-3.189-9.0%€32.33€32.33€32.330
€35.52-1.088-3.0%€35.52€35.52€35.52100
€36.60-0.545-1.5%€36.28€36.95€36.270
€37.15+1.174+3.3%€37.65€37.73€37.100
€35.97-0.45-1.2%€35.97€35.97€35.970
€36.42+0.292+0.8%€35.71€36.68€35.380
€36.13+1.403+4.0%€35.57€36.34€35.540
€34.73-0.307-0.9%€34.73€34.73€34.73754
€35.04-0.375-1.1%€35.04€35.04€35.040
€35.41-0.482-1.3%€35.41€35.41€35.410
€35.89+0.094+0.3%€35.69€35.91€35.640
€35.80+0.106+0.3%€35.62€35.90€35.540
€35.69-1.623-4.3%€36.62€36.80€35.490
€37.32-0.228-0.6%€37.13€37.83€37.030
€37.54+0.0050.0%€37.29€37.66€37.28694
€37.54+0.352+0.9%€37.74€38.08€37.4660
€37.19+1.925+5.5%€37.19€37.19€37.190
€35.26-0.528-1.5%€35.26€35.26€35.260
€35.79-1.388-3.7%€36.07€36.30€35.75700
€37.18+1.403+3.9%€36.04€37.45€35.930
€35.78-2.184-5.8%€35.78€35.78€35.7818
€37.96-0.664-1.7%€37.96€37.96€37.960
€38.62+1.106+2.9%€37.21€38.78€37.200
€37.52+0.207+0.6%€37.46€37.78€37.170
€37.31-0.331-0.9%€37.31€37.31€37.310
€37.64+0.256+0.7%€37.64€37.64€37.64184
€37.39+0.857+2.3%€37.39€37.39€37.390
€36.53+0.405+1.1%€36.53€36.53€36.530
€36.12-0.18-0.5%€36.12€36.12€36.120
€36.30-2.178-5.7%€36.30€36.30€36.300
€38.48-0.251-0.6%€38.48€38.48€38.48184
€38.73-0.822-2.1%€38.73€38.73€38.730
€39.55+1.069+2.8%€39.17€39.76€38.9440
€38.49-0.783-2.0%€38.49€38.49€38.490
€39.27-0.048-0.1%€39.27€39.27€39.27600
€39.32-2.371-5.7%€39.32€39.32€39.320
€41.69-0.904-2.1%€41.69€41.69€41.690
Ticker
Frankfurt:UR8
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Frankfurt
Currency
EUR

What changed lately

Latest news

All UroGen Pharma Ltd. news

UroGen Pharma Ltd. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
31 in the last 12 months · 205 in all · newest Nov 4, 2026 · oldest 2019
Calls
26 calls with a replay · 26 with a transcript · latest Nov 4, 2026
Decks
10 decks · latest August 2026

Where UroGen Pharma Ltd. is listed

ListingExchangeCountryCurrency
NASDAQ:URGN · Home listingNASDAQUnited StatesUSD
LS Exchange:A2DTCVLS ExchangeGermanyEUR
gettex:UR8gettexGermanyEUR
Lang & Schwarz:A2DTCVLang & SchwarzGermanyEUR
LSE:0XODLSEUnited KingdomUSD
BOATS:URGNBOATSUnited StatesUSD
Frankfurt:UR8 · This pageFrankfurtGermanyEUR
Dusseldorf:UR8DusseldorfGermanyEUR
Munich:UR8MunichGermanyEUR
Stuttgart:UR8StuttgartGermanyEUR
Tradegate:UR8TradegateGermanyEUR

Valuation

EV/sales 5.8× against a median of 41.7×: 3rd lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$1.46B USD
P/E
Loss
EV/sales
5.8×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
91.4%
Operating margin
−12.4%
Net margin
−26.3%
Debt to equity
Negative equity
Beta vs S&P 500
1.23

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
UroGen Pharma Ltd. · NASDAQ:URGNUS$1.36BUS$1.46Bn/a5.8×n/an/a−26.3%n/a1.23
ADARx Pharmaceuticals, Inc. · NASDAQ:ADRXUS$1.42BUS$521.8Mn/a77.6×n/a2.5×n/a0.0×n/a
Nurix Therapeutics, Inc. · NASDAQ:NRIXUS$1.40BUS$683.6M4.8×1.0×n/a1.4×42.0%0.0×1.15
Intellia Therapeutics, Inc. · NASDAQ:NTLAUS$1.40BUS$1.00Bn/a19.0×n/a2.3×−805.7%0.1×2.01
Tyra Biosciences, Inc. · NASDAQ:TYRAUS$1.39BUS$694.9Mn/an/an/a2.0×n/a0.0×0.40
Wuhan Healthgen Biotechnology Corp Class A · SSE:688765US$1.37BUS$1.37Bn/a164×n/a3.3×−252.8%0.1×n/a
Rapport Therapeutics, Inc. · NASDAQ:RAPPUS$1.37BUS$987.3Mn/a49.4×n/a3.5×−752.4%0.0×1.16
Immunocore Holdings plc · NASDAQ:IMCRUS$1.36BUS$463.6Mn/a1.1×n/a3.3×−7.5%0.0×0.62
Nanobiotix SA · EURONEXT:NANOUS$1.36BUS$1.36Bn/a41.7×n/an/a−80.8%n/an/a
uniQure N.V. · NASDAQ:QUREUS$1.36BUS$739.1Mn/a36.6×n/a4.6×n/a0.2×1.25
OliX Pharmaceuticals, Inc. · KRX:226950US$1.31BUS$1.16Bn/a114×n/a7.4×−102.9%0.1×n/a
Median of the othersUS$1.37BUS$863.2M4.8×41.7×3.3×−102.9%0.0×1.15

Forecasts

6 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
60.71 USD · Analysts' mean
EPS, year to Dec 2026
-0.37 · 7 analysts
Revenue, year to Dec 2026
319.6M · 7 analysts

Team and board

Officers

OfficerRole
Liz BarrettPresident and Chief Executive Officer
Chris DegnanChief Financial Officer
Jason SmithGeneral Counsel and Chief Compliance Officer
Cindy RomanoDirector, Corporate Communications
Vincent PerroneSenior Director, Investor Relations
Alison HardgroveSVP, Human Resources
Jim OttingerEVP, Regulatory Affairs and Quality
Marina KonortyEVP, Research & Development and Technical Operations
Timothy SimonSVP, Business Development and Portfolio Strategy
Mark P. SchoenbergChief Medical Officer
Michael J. LouieChief Development Officer

Board

DirectorRole
Arie BelldegrunMember of the Compensation Committee
Cynthia M. Butittaof the Audit Committee
Daniel Wildmanof the Compensation Committee; of the Compliance Committee
Jim RobinsonDirector
Leana S. Wenof the Audit Committee; of the Nominating and Corporate Governance Committee
Stuart Holdenof the Audit Committee; of the Compliance Committee

Events

Calls

CallWhenStatus
UroGen Pharma (NASDAQ:URGN) Q3 2026 Earnings CallWed, Nov 04, 2026 · 10:00 AM ETReplay
UroGen Pharma (NASDAQ:URGN) Q2 2026 Earnings CallWed, Aug 05, 2026 · 10:00 AM ETReplay
UroGen Pharma (NASDAQ:URGN) Q1 2026 Earnings CallWed, May 06, 2026 · 10:00 AM ETReplay
UroGen Pharma (NASDAQ:URGN) Q4 2025 Earnings CallMon, Mar 02, 2026 · 10:00 AM ETReplay
UroGen Pharma (NASDAQ:URGN) Q2 2025 Earnings CallThu, Aug 07, 2025 · 10:00 AM ETReplay
UroGen Pharma (NASDAQ:URGN) Q1 2025 Earnings CallMon, May 12, 2025 · 10:00 AM ETReplay
UroGen Pharma (NASDAQ:URGN) Q4 2024 Earnings CallMon, Mar 10, 2025 · 10:00 AM ETReplay
UroGen Pharma (NASDAQ:URGN) Q3 2024 Earnings CallWed, Nov 06, 2024 · 10:00 AM ETReplay
UroGen Pharma (NASDAQ:URGN) Q2 2024 Earnings CallTue, Aug 13, 2024 · 10:00 AM ETReplay
UroGen Pharma (NASDAQ:URGN) Q1 2024 Earnings CallMon, May 13, 2024 · 10:00 AM ETReplay
All 26 calls
CallWhenStatus
UroGen Pharma (NASDAQ:URGN) Q4 2023 Earnings CallThu, Mar 14, 2024 · 10:00 AM ETReplay
UroGen Pharma (NASDAQ:URGN) Q3 2023 Earnings CallTue, Nov 14, 2023 · 10:00 AM ETReplay
UroGen Pharma (NASDAQ:URGN) Q2 2023 Earnings CallThu, Aug 10, 2023 · 10:00 AM ETReplay
UroGen Pharma (NASDAQ:URGN) Q1 2023 Earnings CallThu, May 11, 2023 · 10:00 AM ETReplay
UroGen Pharma (NASDAQ:URGN) Q4 2022 Earnings CallThu, Mar 16, 2023 · 10:00 AM ETReplay
UroGen Pharma (NASDAQ:URGN) Q3 2022 Earnings CallThu, Nov 10, 2022 · 10:00 AM ETReplay
UroGen Pharma (NASDAQ:URGN) Q2 2022 Earnings CallThu, Aug 11, 2022 · 10:00 AM ETReplay
UroGen Pharma (NASDAQ:URGN) Q1 2022 Earnings CallTue, May 10, 2022 · 10:00 AM ETReplay
UroGen Pharma (NASDAQ:URGN) Q4 2021 Earnings CallMon, Mar 21, 2022 · 10:00 AM ETReplay
UroGen Pharma (NASDAQ:URGN) Q3 2021 Earnings CallMon, Nov 15, 2021 · 10:00 AM ETReplay
UroGen Pharma (NASDAQ:URGN) Q2 2021 Earnings CallWed, Aug 04, 2021 · 8:30 AM ETReplay
UroGen Pharma (NASDAQ:URGN) Q1 2021 Earnings CallThu, May 13, 2021 · 8:30 AM ETReplay
UroGen Pharma (NASDAQ:URGN) Q4 2020 Earnings CallThu, Mar 18, 2021 · 8:30 AM ETReplay
UroGen Pharma (NASDAQ:URGN) Q3 2020 Earnings CallMon, Nov 09, 2020 · 8:30 AM ETReplay
UroGen Pharma (NASDAQ:URGN) Q2 2020 Earnings CallMon, Aug 10, 2020 · 8:30 AM ETReplay
UroGen Pharma (NASDAQ:URGN) Q1 2020 Earnings CallThu, May 07, 2020 · 8:30 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 4, 2026 · Before open−16.4%
Q2 2026Aug 5, 2026 · Before open+16.3%
Q1 2026May 6, 2026 · Before open+10.2%
Q4 2025Mar 2, 2026−13.3%
Q3 2025Nov 6, 2025 · Before open+21.9%
Q2 2025Aug 7, 2025 · Before open−7.1%
Q1 2025May 12, 2025 · Before open+7.3%
Q4 2024Mar 12, 2025 · Before open0.0%
Q3 2024Nov 6, 2024 · Before open+0.3%
Q2 2024Aug 13, 2024 · Before open+3.1%
All 20 quarters
QuarterResultsShare move
Q1 2024May 13, 2024 · Before open+2.6%
Q4 2023Mar 14, 2024 · Before open−18.0%
Q3 2023Nov 14, 2023 · Before open−0.7%
Q2 2023Aug 10, 2023 · Before open+2.5%
Q1 2023May 11, 2023 · Before open+8.0%
Q4 2022Mar 16, 2023 · Before open−3.1%
Q3 2022Nov 10, 2022 · Before open−16.3%
Q2 2022Aug 11, 2022 · Before open−6.5%
Q1 2022May 10, 2022 · Before open+6.0%
Q4 2021Mar 21, 2022 · Before open+0.1%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (August 2026)Investor deck30 slidesAugust 2026
Investor Presentation (January 2025)Investor deck44 slidesJan 14, 2025
Technical Presentation (June 2024)Technical57 slidesJun 13, 2024
Investor Presentation (March 2024)Investor deck56 slidesMar 4, 2024
Investor Presentation (February 2024)Investor deck53 slidesFeb 7, 2024
Technical Presentation (July 2023)Technical84 slidesJul 27, 2023
Technical Presentation (July 2023)Technical17 slidesJul 27, 2023
J.P. Morgan 2021 Healthcare ConferenceConference29 slidesJan 11, 2021
Investor Day (September 2019)Investor day68 slidesSep 24, 2019
Investor Presentation (January 2018)Investor deck25 slidesJan 8, 2018

Open Decks

Financings

RaiseDate
Strategic investment of equity securities
Announced: up to US$7M
Buyers: UroGen Pharma Ltd. (up to $7 million in the equity securities of IntraGel)
Use of proceeds: Phase 2 clinical development of TumoCure for advanced head and neck cancer
Aug 20, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$13.00 a share on May 3, 2017.

Price
US$13.00 a share
Shares offered
4,473,373 ordinary shares
Offering size
US$58.2 million
Underwriters' option
Up to 671,005 more shares
Underwriters
Jefferies, Cowen and Company, Raymond James, Oppenheimer & Co. · In the order on the cover
Shares delivered
On or about May 9, 2017

Steps

StepWhen
Draft sent to the SEC in confidenceMar 4, 2016
Filed publiclyApr 7, 2017
Amended onceApr 24, 2017
Shares registered with an exchangeMay 1, 2017
Declared effective by the SECMay 3, 2017
Final prospectus, with the priceMay 5, 2017

Open IPO · From the cover of the final prospectus (424B4) filed May 5, 2017

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue109.8M90.4M82.7M64.4M48.0M11.8M18.0K1.13M8.16M17.5M
Cost of revenue12.4M8.88M9.36M7.65M5.16M1.01M48.0K1.80M600.0K28.0K
Gross profit97.3M81.5M73.4M56.7M42.9M10.8M18.0K-675.0K7.56M17.5M
Research and development67.1M57.1M45.6M52.9M47.6M47.3M49.3M36.9M18.7M10.3M
Selling, general and administrative155.1M121.2M93.3M82.8M87.5M90.2M60.2M39.6M8.81M6.42M
Operating income-124.9M-96.8M-65.5M-79.0M-92.3M-126.7M-109.5M-77.2M-19.9M798.0K
Depreciation and amortization307.0K329.0K802.0K924.0K831.0K416.0K300.0K400.0K200.0K200.0K
EBITDA-124.6M-96.5M-64.7M-78.1M-91.5M-126.3M-109.2M-76.8M-19.8M998.0K
Interest expense33.8M12.5M14.7M8.44M17.4M3.67M284.0K000
Income before tax-153.4M-124.0M-98.3M-108.0M-109.4M-125.1M-105.1M-75.5M-20.0M-1.94M
Income tax78.0K2.83M3.92M1.75M1.45M3.37M-4.62M125.0K19.0K0
Net income-153.5M-126.9M-102.2M-109.8M-110.8M-128.5M-105.1M-75.7M-20.0M-1.94M
Earnings per share, basic-3.19-2.96-3.55-4.81-4.96-5.90-5.12-4.80-2.14-1.91
Earnings per share, diluted-4.96-5.90-5.12-4.80-2.14-1.91

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents110.7M172.0M95.0M55.4M44.4M52.9M49.7M101.3M37.0M21.4M
Short-term investments49.3M110.7M56.2M44.6M44.8M49.2M97.4M36.0M95.0K
Receivables33.1M20.3M15.4M12.7M11.7M7.05M198.0K83.0K
Inventory16.5M9.23M5.67M4.33M4.83M1.96M316.0K105.0K
Current assets186.0M276.1M169.2M128.9M114.4M115.6M148.6M102.2M74.5M22.0M
Property, plant and equipment637.0K655.0K689.0K1.30M1.97M2.05M977.0K948.0K805.0K741.0K
Total assets200.5M285.7M178.3M135.6M119.7M122.0M202.4M103.6M75.5M23.1M
Accounts payable12.1M10.9M6.51M5.53M5.79M3.27M4.69M4.27M2.84M1.88M
Current liabilities46.4M45.9M31.2M23.9M22.4M21.4M19.5M13.5M7.04M3.14M
Long-term debt122.2M121.7M98.6M97.5M03.61M
Total debt125.0M121.7M98.6M97.5M01.50M2.60M
Total liabilities305.9M294.5M243.5M225.0M111.3M25.6M22.1M13.5M7.04M6.75M
Shareholders' equity-105.5M-8.80M-65.2M-89.4M8.41M96.4M180.3M90.1M68.5M16.3M
Shares outstanding48.4M42.2M32.5M23.1M22.5M22.2M21.0M16.2M13.8M2.31M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-162.4M-96.8M-76.4M-87.6M-84.9M-105.9M-71.0M-37.3M-9.57M4.19M
Capital spending-289.0K-295.0K-194.0K-254.0K-752.0K-1.22M-325.0K-560.0K-271.0K-695.0K
Free cash flow-162.7M-97.1M-76.6M-87.8M-85.6M-107.1M-71.3M-37.9M-9.84M3.49M
Cash from investing61.6M-20.6M-953.0K1.06M4.07M93.2M-145.6M35.3M-36.3M-719.0K
Cash from financing39.9M194.6M116.9M97.1M72.3M16.5M165.3M66.4M61.6M-9.00K
Share buybacks1.35M-83.0K16.5M165.3M66.6M61.6M570.0K
Change in cash-61.0M77.2M39.6M10.6M-8.50M3.88M-51.4M64.4M15.7M3.46M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansNov 4, 2026Offer documentSEC
10-Q · Quarterly reportNov 4, 2026Quarterly reportSEC
8-K · Current reportNov 4, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 27, 2026Big-stake noticeSEC
4 · Change in ownershipOct 9, 2026Insider tradeSEC
144 · Notice of proposed saleOct 9, 2026Other filingsSEC
4 · Change in ownershipSep 9, 2026Insider tradeSEC
4 · Change in ownershipSep 9, 2026Insider tradeSEC
144 · Notice of proposed saleSep 9, 2026Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
144 · Notice of proposed saleSep 9, 2026Other filingsSEC
4 · Change in ownershipAug 28, 2026Insider tradeSEC
4 · Change in ownershipAug 24, 2026Insider tradeSEC
144 · Notice of proposed saleAug 20, 2026Other filingsSEC
8-K · Current reportAug 20, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 12, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 5, 2026Quarterly reportSEC
8-K · Current reportAug 5, 2026ResultsSEC
4 · Change in ownershipJul 10, 2026Insider tradeSEC
144 · Notice of proposed saleJul 9, 2026Other filingsSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
8-K · Current reportJun 23, 2026Management or board changeSEC
144 · Notice of proposed saleJun 22, 2026Other filingsSEC
4 · Change in ownershipJun 9, 2026Insider tradeSEC
144 · Notice of proposed saleJun 9, 2026Other filingsSEC
8-K · Current reportJun 2, 2026Current reportSEC
ARS · Annual report to shareholdersMay 27, 2026Annual reportSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
4 · Change in ownershipMay 11, 2026Insider tradeSEC
144 · Notice of proposed saleMay 8, 2026Other filingsSEC
10-Q · Quarterly reportMay 6, 2026Quarterly reportSEC
8-K · Current reportMay 6, 2026ResultsSEC
DEF 14A · Proxy statementApr 30, 2026Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeApr 27, 2026Big-stake noticeSEC
PRE 14A · Preliminary proxy statementApr 17, 2026Meeting noticeSEC
10-K · Annual reportMar 2, 2026Annual reportSEC
8-K · Current reportMar 2, 2026ResultsSEC
8-K · Current reportMar 2, 2026Material contractSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 3, 2026Other filingsSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
4 · Change in ownershipNov 20, 2025Insider tradeSEC
144 · Notice of proposed saleNov 19, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
S-8 · Registration statement for employee plansNov 6, 2025Offer documentSEC
S-3ASR · Registration statementNov 6, 2025Offer documentSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
4 · Change in ownershipOct 9, 2025Insider tradeSEC
4 · Change in ownershipSep 9, 2025Insider tradeSEC
4 · Change in ownershipSep 9, 2025Insider tradeSEC
144 · Notice of proposed saleSep 9, 2025Other filingsSEC
144 · Notice of proposed saleSep 9, 2025Other filingsSEC
4 · Change in ownershipAug 27, 2025Insider tradeSEC
4 · Change in ownershipAug 27, 2025Insider tradeSEC
4 · Change in ownershipAug 27, 2025Insider tradeSEC
4 · Change in ownershipAug 27, 2025Insider tradeSEC
4 · Change in ownershipAug 27, 2025Insider tradeSEC
4 · Change in ownershipAug 27, 2025Insider tradeSEC
8-K · Current reportAug 27, 2025Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
4 · Change in ownershipAug 13, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeAug 12, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeAug 6, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 5, 2025Big-stake noticeSEC
4 · Change in ownershipJul 30, 2025Insider tradeSEC
4 · Change in ownershipJul 30, 2025Insider tradeSEC
4 · Change in ownershipJul 30, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 29, 2025Big-stake noticeSEC
144 · Notice of proposed saleJul 29, 2025Other filingsSEC
144 · Notice of proposed saleJul 29, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 16, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersJul 16, 2025Annual reportSEC
DEF 14A · Proxy statementJul 15, 2025Meeting noticeSEC
8-K · Current reportJul 3, 2025Management or board changeSEC
SCHEDULE 13G · Big-stake noticeJun 16, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJun 13, 2025Big-stake noticeSEC
8-K · Current reportJun 13, 2025Current reportSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
144 · Notice of proposed saleJun 10, 2025Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 9, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 12, 2025Quarterly reportSEC
8-K · Current reportMay 12, 2025ResultsSEC
10-K/A · Annual report, amendedApr 30, 2025Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 17, 2025Big-stake noticeSEC
10-K · Annual reportMar 10, 2025Annual reportSEC
8-K · Current reportMar 10, 2025ResultsSEC
8-K · Current reportFeb 20, 2025Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 5, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
8-K · Current reportJan 14, 2025Current reportSEC
SC 13D/A · Big-stake notice, amendedNov 18, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 12, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 6, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2024Quarterly reportSEC
8-K · Current reportNov 6, 2024ResultsSEC
SC 13G · Big-stake noticeOct 24, 2024Big-stake noticeSEC
4 · Change in ownershipOct 9, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 9, 2024Insider tradeSEC
8-K · Current reportOct 9, 2024Management or board changeSEC
8-K · Current reportSep 24, 2024FinancingSEC
8-K · Current reportSep 13, 2024Management or board changeSEC
4 · Change in ownershipSep 12, 2024Insider tradeSEC
4 · Change in ownershipSep 12, 2024Insider tradeSEC
4 · Change in ownershipSep 12, 2024Insider tradeSEC
144 · Notice of proposed saleSep 10, 2024Other filingsSEC
8-K · Current reportAug 15, 2024Current reportSEC
S-8 · Registration statement for employee plansAug 13, 2024Offer documentSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
8-K · Current reportAug 13, 2024ResultsSEC
8-K · Current reportAug 8, 2024Management or board changeSEC
4 · Change in ownershipAug 8, 2024Insider tradeSEC
4 · Change in ownershipAug 8, 2024Insider tradeSEC
4 · Change in ownershipAug 8, 2024Insider tradeSEC
4 · Change in ownershipAug 8, 2024Insider tradeSEC
4 · Change in ownershipAug 8, 2024Insider tradeSEC
4 · Change in ownershipAug 8, 2024Insider tradeSEC
4 · Change in ownershipAug 8, 2024Insider tradeSEC
ARS · Annual report to shareholdersJul 9, 2024Annual reportSEC
DEFA14A · Additional proxy materialJul 1, 2024Meeting noticeSEC
DEF 14A · Proxy statementJul 1, 2024Meeting noticeSEC
SC 13G · Big-stake noticeJun 24, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeJun 24, 2024Big-stake noticeSEC
8-K · Current reportJun 18, 2024Material contractSEC
424B5 · ProspectusJun 18, 2024Offer documentSEC
424B5 · ProspectusJun 17, 2024Offer documentSEC
8-K · Current reportJun 13, 2024Current reportSEC
4 · Change in ownershipJun 11, 2024Insider tradeSEC
144 · Notice of proposed saleJun 11, 2024Other filingsSEC
10-Q · Quarterly reportMay 13, 2024Quarterly reportSEC
8-K · Current reportMay 13, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedMay 8, 2024Big-stake noticeSEC
10-K/A · Annual report, amendedApr 29, 2024Annual reportSEC
4 · Change in ownershipMar 20, 2024Insider tradeSEC
144 · Notice of proposed saleMar 18, 2024Other filingsSEC
10-K · Annual reportMar 14, 2024Annual reportSEC
8-K · Current reportMar 14, 2024ResultsSEC
8-K · Current reportMar 4, 2024Current reportSEC
8-K · Current reportMar 1, 2024Current reportSEC
SC 13D/A · Big-stake notice, amendedFeb 22, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
4/A · Change in ownership, amendedFeb 12, 2024Insider tradeSEC
4/A · Change in ownership, amendedFeb 12, 2024Insider tradeSEC
8-K · Current reportFeb 7, 2024Current reportSEC
4/A · Change in ownership, amendedFeb 5, 2024Insider tradeSEC
4/A · Change in ownership, amendedFeb 5, 2024Insider tradeSEC
4 · Change in ownershipFeb 2, 2024Insider tradeSEC
4 · Change in ownershipFeb 2, 2024Insider tradeSEC
4 · Change in ownershipFeb 2, 2024Insider tradeSEC
4 · Change in ownershipFeb 2, 2024Insider tradeSEC
SC 13G · Big-stake noticeFeb 2, 2024Big-stake noticeSEC
144 · Notice of proposed saleFeb 1, 2024Other filingsSEC
144 · Notice of proposed saleFeb 1, 2024Other filingsSEC
8-K · Current reportJan 17, 2024Material contractSEC
8-K · Current reportJan 2, 2024Material contractSEC
SC 13G · Big-stake noticeDec 29, 2023Big-stake noticeSEC
UPLOAD · Letter from the SECDec 5, 2023Other filingsSEC
CORRESP · Letter to the SECNov 27, 2023Other filingsSEC
UPLOAD · Letter from the SECNov 16, 2023Other filingsSEC
S-8 · Registration statement for employee plansNov 14, 2023Offer documentSEC
10-Q · Quarterly reportNov 14, 2023Quarterly reportSEC
8-K · Current reportNov 14, 2023ResultsSEC

This page holds 200 of 584 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from UroGen Pharma Ltd.’s releases · as of Aug 20, 2026

Common shares
49,047,823
Fully diluted
49,047,823

Fully diluted

LineShares
Common shares49,047,823

Share count over time

CountShares
Nov 22, 202649,047,823

Open Cap table

Shareholders

Funds

HolderSharesValueAs of
iShares Russell 2000 ETF1.11MUS$40.8MJun 30, 2026
Small Cap Growth Fund875KUS$33.5MJul 31, 2026
Fidelity Small Cap Index Fund465KUS$17.8MJul 31, 2026
iShares Russell 2000 Growth ETF339KUS$12.5MJun 30, 2026
iShares Biotechnology ETF290KUS$10.7MJun 30, 2026
Vanguard Russell 2000 Index Fund207KUS$5.82MMay 31, 2026
Vanguard Explorer Value Fund190KUS$5.34MMay 31, 2026
State Street(R) SPDR(R) Portfolio Developed World ex-US ETF185KUS$6.8MJun 30, 2026
Fidelity Enhanced Small Cap Core ETF176KUS$6.46MJun 30, 2026
iShares Micro-Cap ETF143KUS$5.27MJun 30, 2026
Show 50 holders
HolderSharesValueAs of
Vanguard Health Care Index Fund118KUS$3.33MMay 31, 2026
Schwab Small-Cap Index Fund103KUS$3.96MJul 31, 2026
Calamos Timpani Small Cap Growth Fund97,953US$3.75MJul 31, 2026
Small Cap Growth Fund94,936US$2.67MMay 31, 2026
BlackRock Advantage Small Cap Core Fund89,168US$2.51MMay 29, 2026
Master Small Cap Index Series79,645US$2.93MJun 30, 2026
Clearwater Select Equity Fund67,706US$2.49MJun 30, 2026
Federated Hermes MDT Small Cap Growth Fund60,521US$2.31MJul 31, 2026
Tema Oncology ETF58,518US$1.65MMay 31, 2026
ARK Israel Innovative Technology ETF54,250US$2.07MJul 31, 2026
Nuveen Small Cap Blend Index Fund52,750US$2.02MJul 31, 2026
iShares Russell 2000 Value ETF52,288US$1.92MJun 30, 2026
EQ/2000 Managed Volatility Portfolio46,239US$1.7MJun 30, 2026
Amplify BlueStar Israel Technology ETF43,319US$1.59MJun 30, 2026
U.S. Small Cap Equity Fund37,512US$1.43MJul 31, 2026
M Capital Appreciation Fund37,221US$669KMar 31, 2026
M Capital Appreciation Fund36,861US$1.36MJun 30, 2026
Nuveen Equity Index Fund34,807US$1.33MJul 31, 2026
Fidelity Small Cap Growth Index Fund34,456US$1.27MJun 30, 2026
Vanguard U.S. Momentum Factor ETF33,104US$931KMay 31, 2026
Vanguard Russell 2000 Growth Index Fund31,194US$877KMay 31, 2026
Fidelity Nasdaq Composite Index Fund30,686US$863KMay 31, 2026
iShares U.S. Small-Cap Equity Factor ETF30,659US$1.17MJul 31, 2026
LVIP State Street Small-Cap Index Fund30,200US$1.11MJun 30, 2026
State Street(R) SPDR(R) S&P(R) International Small Cap ETF25,821US$950KJun 30, 2026
EQ/Small Company Index Portfolio25,250US$929KJun 30, 2026
Schwab Small-Cap Equity Fund23,370US$894KJul 31, 2026
Goldman Sachs ActiveBeta(R) U.S. Small Cap Equity ETF21,882US$616KMay 31, 2026
Small Cap Index Fund21,528US$792KJun 30, 2026
Global X Russell 2000 ETF20,398US$780KJul 31, 2026
VIP Disciplined Small Cap Portfolio19,515US$718KJun 30, 2026
Fidelity MSCI Health Care Index ETF18,561US$710KJul 31, 2026
Global Small Cap Fund17,772US$500KMay 31, 2026
LVIP Franklin Templeton Multi-Factor SMID Cap Equity Fund17,633US$649KJun 30, 2026
Small Cap Index Fund15,749US$443KMay 31, 2026
iShares Russell 3000 ETF15,036US$553KJun 30, 2026
Column Small Cap Fund14,607US$411KMay 31, 2026
Fidelity Nasdaq Composite Index ETF14,314US$403KMay 31, 2026
AQR Small Cap Multi-Style Fund14,273US$525KJun 30, 2026
State Street Small/Mid Cap Equity Index Portfolio14,200US$523KJun 30, 2026

This page holds 50 of 133 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Degnan Chris
Officer: Chief Financial Officer
Sale2,202USD 36.69US$80,791Oct 8, 2026
Smith Jason Drew
Officer: General Counsel
Sale1,519USD 42.54US$64,618Sep 8, 2026
Schoenberg Mark
Officer: Chief Medical Officer
Sale871USD 42.92US$37,383Sep 8, 2026
Schoenberg Mark
Officer: Chief Medical Officer
Sale60,677USD 47.05US$2.85MAug 20, 2026
Schoenberg Mark
Officer: Chief Medical Officer
Sale10,000USD 40.00US$400KJul 9, 2026
Schoenberg Mark
Officer: Chief Medical Officer
Sale10,000USD 35.01US$350KJun 22, 2026
Schoenberg Mark
Officer: Chief Medical Officer
Sale5,222USD 27.30US$143KJun 8, 2026
Schoenberg Mark
Officer: Chief Medical Officer
Sale10,000USD 30.00US$300KMay 8, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Kathryn Falberg
Other companies: Nuvation Bio Inc. (Board of Directors · Since at least Feb 10, 2021); Arcus Biosciences, Inc. (Board Member · Since at least Mar 14, 2018); The Trade Desk, Inc. (Director · Since at least Sep 20, 2016); Tricida Inc (Director · Jun 27, 2018 – Jun 15, 2022 · Past); Sio Gene Therapies Inc (Director · Apr 7, 2017 – May 15, 2017 · Past); BioMarin Pharmaceutical Inc. (Director · Jul 15, 2016 – Jul 15, 2016 · Past); Aimmune Therapeutics Inc (Director · Aug 5, 2015 – Oct 10, 2020 · Past); aTyr Pharma, Inc. (Director · May 6, 2015 – May 24, 2016 · Past); Medivation Inc (Director · Jan 31, 2013 – Sep 28, 2016 · Past); Jazz Pharmaceuticals plc (EVP and CFO · Dec 1, 2009 – Mar 5, 2014 · Past); Novelion Therapeutics Inc (Director · Mar 25, 2009 – May 26, 2011 · Past); Oruka Therapeutics, Inc. (CFO and COO · Feb 23, 2009 – Jun 25, 2009 · Past); Halozyme Therapeutics, Inc. (Director · May 15, 2007 – May 4, 2016 · Past)
Director · Jan 1, 2019 – Jun 7, 2021 · Past
Peter P Pfreundschuh
Other companies: Y mAbs Therapeutics (EVP, CFO and Treasurer · Since at least Jun 28, 2024); Voyager Therapeutics, Inc. (Chief Financial Officer · Sep 19, 2022 – Feb 21, 2024 · Past); Korro Bio, Inc. (Chief Financial Officer · Dec 1, 2020 – Feb 18, 2022 · Past); Sucampo Pharmaceuticals Inc (CFO · Mar 20, 2017 – Feb 13, 2018 · Past); Immunomedics Inc (Chief Financial Officer · Aug 20, 2015 – Aug 20, 2015 · Past)
Chief Financial Officer · Jan 1, 2019 – Oct 15, 2020 · Past
Shawn Tomasello
Other companies: Cabaletta Bio, Inc. (Director · Since at least Jul 21, 2023); 4D Molecular Therapeutics, Inc. (Director · Since at least Dec 10, 2020); Kalaris Therapeutics, Inc. (Director · Mar 29, 2022 – Jun 6, 2024 · Past); Gamida Cell Ltd (Director · Jan 1, 2022 – Jan 31, 2024 · Past); Tcr2 Therapeutics Inc (Director · Feb 3, 2021 – Jun 1, 2023 · Past)
Director · Jun 7, 2021 – Jun 7, 2021 · Past
Cynthia M. Butitta
Other companies: Autolus Therapeutics plc (Chair of the Compensation Committee, Member of the Audit Committee · Since at least Mar 18, 2026); Century Therapeutics, Inc. (Director · Since at least Jun 17, 2021); Olema Pharmaceuticals, Inc. (Director · Since at least Aug 12, 2020); Kite Pharma Inc (Chief Operating Officer · Jun 19, 2014 – Oct 3, 2017 · Past)
of the Audit Committee · Since at least Jan 1, 2019
James A Robinson Jr
Other companies: Eledon Pharmaceuticals, Inc. (Director · Since at least Oct 1, 2023); Urovant Sciences Ltd (PEO;CEO/Urovant Sciences, Inc., Director · Mar 1, 2019 – Mar 29, 2021 · Past); Neos Therapeutics Inc (Director · Jan 29, 2019 – Mar 19, 2021 · Past); Alkermes plc (President & COO,Alkermes, Inc. · Mar 5, 2018 – Apr 4, 2019 · Past)
Director · Since at least Jul 25, 2023
Molly Henderson
Other companies: Phathom Pharmaceuticals, Inc. (CFO and CBO · Apr 5, 2022 – Apr 7, 2025 · Past); Advaxis Inc (Executive Vice President & CFO · Jun 6, 2018 – May 4, 2020 · Past); Iovance Biotherapeutics, Inc. (CFO · Jun 8, 2015 – Jun 1, 2016 · Past); VirtualScopics Inc (Chief Business/Financial Off. · May 30, 2006 – Jan 29, 2013 · Past)
Chief Financial Officer · Oct 1, 2020 – Jan 31, 2022 · Past
Arie Belldegrun
Other companies: Allogene Therapeutics, Inc. (Director · Since at least Mar 26, 2021); Kronos Bio Inc (Director · Since at least Oct 8, 2020); Ginkgo Bioworks Holdings, Inc. (Director · Sep 16, 2021 – Jun 12, 2024 · Past)
Director · Since at least Mar 24, 2021
Elizabeth A Barrett
Other companies: Sage Therapeutics Inc (Director · Since at least Jun 11, 2025); Allogene Therapeutics, Inc. (Director · Since at least Jul 30, 2021); LifeSci Acquisition II Corp (Director · Nov 20, 2020 – Nov 20, 2020 · Past)
Chief Executive Officer · Since at least Jan 3, 2019
Chris Degnan
Other companies: Galera Therapeutics, Inc. (Chief Financial Officer · Nov 6, 2019 – Mar 13, 2023 · Past); Verrica Pharmaceuticals Inc. (Chief Financial Officer · Jun 14, 2018 – Feb 28, 2019 · Past)
Chief Financial Officer · Since at least Oct 8, 2024
Dong Kim
Other companies: Canton Strategic Holdings, Inc. (CFO · Mar 27, 2025 – Mar 27, 2025 · Past)
Chief Financial Officer · Mar 25, 2022 – Sep 9, 2024 · Past
All 26 people
PersonSeat
Leana S. Wen
Other companies: Glaukos Corporation (Director · Since at least Mar 1, 2021)
Director · Since at least Sep 8, 2022
Liz Barrett
Other companies: Allogene Therapeutics, Inc. (President and Chief Executive Officer of UroGen, Former CEO of Novartis Oncology · Since at least Nov 6, 2026)
President and Chief Executive Officer · Since at least Nov 4, 2026
Alison HardgroveSVP, Human Resources · Since at least Nov 5, 2026
Chris DegnanChief Financial Officer · Since at least Mar 2, 2026
Cindy RomanoDirector, Corporate Communications · Since at least Nov 3, 2026
Daniel Wildmanof the Compensation Committee; of the Compliance Committee · Since at least Nov 5, 2026
Jason SmithGeneral Counsel and Chief Compliance Officer · Since at least Aug 31, 2020
Jim OttingerEVP, Regulatory Affairs and Quality · Since at least Nov 4, 2026
Jim RobinsonDirector · Since at least Aug 28, 2026
Marina KonortyEVP, Research & Development and Technical Operations · Since at least Nov 5, 2026
Mark P. SchoenbergChief Medical Officer · Since at least Jan 1, 2019
Michael J. LouieChief Development Officer · Since at least Jul 7, 2025
Stephen MullennixChief Operating Officer · Jan 1, 2019 – Apr 26, 2020 · Past
Stuart Holdenof the Audit Committee; of the Compliance Committee · Since at least Jan 1, 2019
Timothy SimonSVP, Business Development and Portfolio Strategy · Since at least Nov 5, 2026
Vincent PerroneSenior Director, Investor Relations · Since at least Nov 3, 2026

Open People

Log in to ask 6ix AI your own questions about UroGen Pharma Ltd.